Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.
Bill Whitaker is an award-winning journalist and 60 Minutes correspondent who has covered major news stories, domestically and across the globe, for more than four decades with CBS News. America's ...
Crispr stock yo-yoed while Intellia stock surged, on promising updates for their gene-editing efforts in cholesterol treatment and a swelling disorder. At the American Heart Association conference in ...
Genomics and genome editing tools took center stage this year, from the Breakthrough Prize in Life Sciences honoring the development of base editing and prime editing to the controversy surrounding ...
The damage to the body caused by the most common type of inherited kidney disease was thought to be irreversible. But now, animal studies suggest that correcting the responsible mutations via CRISPR ...
In a study published in Nature Communications titled “Construction of multi-targeted CRISPR libraries in tomato to overcome functional redundancy at genome-scale level,” researchers from Tel Aviv ...
-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in ...
Please provide your email address to receive an email when new articles are posted on . A CRISPR-Cas9-based therapy reduced transthyretin levels in patients with hereditary amyloidosis and ...
A gene-editing therapy led to durable changes in serum transthyretin levels among people with hereditary transthyretin amyloidosis with polyneuropathy. Polyneuropathy stages and disability scores were ...
Crispr gene-editing technology has demonstrated its revolutionary potential in recent years: It has been used to treat rare diseases, to adapt crops to withstand the extremes of climate change, or ...
In a step toward the wider use of gene editing, a treatment that uses Crispr successfully slashed high cholesterol levels in a small number of people. In a trial conducted by Swiss biotech company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results